Expertise in
7
conditions

S S. Sridhar

700 University Avenue, 
Toronto, ON, CA 
Expertise in
7
conditions
700 University Avenue, 
Toronto, ON, CA 

Overview

S Sridhar practices practicing medicine in Toronto, Canada.

Sridhar is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

They are actively involved in clinical research, co-authoring 226 peer reviewed articles and participating in 9 clinical trials.

Locations

700 University Avenue, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy
A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Other, Drug
Study Drug: Avelumab
Study Phase: Phase 2
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
Enrollment Status: Terminated
Publish Date: April 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Unknown
Publish Date: January 24, 2024
Intervention Type: Drug
Study Drugs: Dexamethasone, Radium-223 Dichloride
Study Phase: Phase 4
A Multicenter Randomized Double Blind Study Examining the Efficacy and Safety of Denosumab in Combination With First Line Platinum-based Chemotherapy for Patients With Bone Metastasis Secondary to Metastatic Urothelial Cancer
A Multicenter Randomized Double Blind Study Examining the Efficacy and Safety of Denosumab in Combination With First Line Platinum-based Chemotherapy for Patients With Bone Metastasis Secondary to Metastatic Urothelial Cancer
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug, Dietary supplement, Other
Study Drugs: Denosumab, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 2
A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients
A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients
Enrollment Status: Completed
Publish Date: September 01, 2021
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole
Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole
Enrollment Status: Completed
Publish Date: May 13, 2021
Intervention Type: Drug
Study Phase: Not Applicable
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
Enrollment Status: Completed
Publish Date: March 23, 2021
Intervention Type: Radiation
Study Phase: Phase 2
A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
Enrollment Status: Unknown
Publish Date: December 06, 2017
Intervention Type: Drug
Study Drugs: Cabazitaxel, Abiraterone, Enzalutamide
Study Phase: Phase 2
View 8 Less Clinical Trials

226 Total Publications

A New Standard in Muscle-Invasive Bladder Cancer - The End of the Cisplatin Era?
A New Standard in Muscle-Invasive Bladder Cancer - The End of the Cisplatin Era?
Journal: The New England journal of medicine
Published: July 22, 2026

Frequently Asked Questions about S S. Sridhar

Is S S. Sridhar a top-rated expert for Urothelial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. S S. Sridhar is classified as an Distinguished expert for Urothelial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does S S. Sridhar participate in research or clinical trials?

Yes. S S. Sridhar has published 226 articles and abstracts on conditions like Urothelial Cancer. You can view a list of S S. Sridhar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sridhar's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile